It was a relief to see that children and adolescents suffered less from severe physical effects of COVID-19. However, they seem to be paying a heavy price when it comes to mental health.
Hi, I am Camille Rigaud from Kieger.
A summary of many studies, covering over 80,000 children and adolescents globally, concluded that over the course of the pandemic, one in four youth experienced depression symptoms and one in five anxiety symptoms, a number which has doubled.
Pre-pandemic, around 166 million adolescents age 10-19 lived with a mental disorder. Despite the size of the challenge, only 2% of government health budgets are spent on mental health. Beyond the traditional antidepressants there has been very little innovation and therapies are primarily being developed for adults.
There is a huge unmet need. Large healthcare companies have not been investing in the space due to the unattractive risk / reward profile. There is a high risk of failure in clinical trials due to high placebo effect and today we still know very little about how the brain works.
This is why mental health really matters to us, we are constantly looking for new solutions to help the most vulnerable.
40.97% - that's how much the HC market has returned since November 2019 until end of November 2022. It certainly has not been a straight line. Join our Kieger Healthcare specialists Urban Fritsche and Raphael Oesch as they look back at the last three healthcare investment years and discuss two current challenges and corresponding opportunities.
Day after day currently feels like a roller coaster ride, going up because of better than hoped for CPI numbers, down because of looming recession fears, and back up because of a less hawkish FED speech. Are we there yet? What do you think?
Our goal is to contribute to the achievement of health-related UN Sustainable Development Goals (SDGs), supporting innovative solutions that address global health challenges, driving awareness and helping and help signal/highlight funding disparities.